New Softgel Solutions for Abuse Deterrence, Macromolecular Encapsulation, Controlled Release and Semi-Solid Formulations
While Softgel Technology is the delivery solution for solubility and bioavailability challenges, recent innovations have expanded the utility of softgel to solve challenges in the abuse deterrent, macromolecular encapsulation, as well as now offering an even wider range of molecules, excipients and fill formulations including extended release with a non-gelatin shell.
This webinar will provide a detailed review of these advancements in Softgel delivery technology and how it can enable even more products a faster path to market.
1. A review of a softgel development program and how new technology and capabilities can quickly bring an optimal formulation to commercial supply, without the pitfalls of some other technologies.
2. The expanded capability of OptiShellâ„¢ technology now enabling more molecules, semi-solid fills, &controlled release profiles in a softgel dose form.
3. Review of OptiGel Lockâ„¢ offering multi-level abuse deterrence through inhalation prevention, reducing syringability and preventing extraction.
4. IV to Oral Conversion of macromolecules through OptiGel Bioâ„¢ technology.
Sign up to today to discover how these new technologies can transform your therapy and how a Softgel Development program can deliver your most challenging poorly bioavailable, controlled release, abuse deterrent, and macromolecules, to market faster than ever before.
Presented by
Stephan Tindal,
Director, Softgel Formulation and Site R&D Lead
Stephen joined Catalent 27 years ago when he began working for RP Scherer (UK) Ltd. He is currently Director, Softgel Formulation at Catalent Headquarters in Somerset, NJ. Stephen holds a B.Sc. Honors Degree in Chemistry & Analytical Science from Loughborough University, England.
Norman Stroud,
Director, Technology Development
Mr. Stroud began his career working in the Pharmaceutics Department, School of Pharmacy and Pharmacology, University of Bath, England. During his time in academia, Mr. Stroud held various positions in Pharmaceutical Research and Development, with a focus on the development of liquid dosage forms. Mr. Stroud received his B.Sc (Hons) degree in Biochemistry from Cardiff University, Wales and has been granted eight U.S. patents.
Julien Meissonnier,
Director, R&d Platform - Rx Softgel
Mr. Meissonnier provides technical and scientific leadership for the development of delivery systems for poorly soluble drugs that lead to approvable regulatory dossiers. His responsibilities include early stage screening activities, developing products, scale-up and technology transfer, directing clinical supplies and supporting product launches. Mr. Meissonnier has 12 years of experience in pharmaceutical development. He received his Engineer Degree in Physico-Chemistry from the ENSI in Caen, France.
